We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Study to Evaluate the Efficacy and Safety of Nintedanib (BIBF 1120) + Prednisone Taper in Patients With Radiation Pneumonitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02496585
Recruitment Status : Active, not recruiting
First Posted : July 14, 2015
Last Update Posted : July 20, 2022
Boehringer Ingelheim
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center

Brief Summary:
The purpose of this study is to find out what effects, good and/or bad, the drug nintedanib in combination with steroids, has on the lungs. Furthermore, such treatments' side effects will be studied together with quality of life. In addition, the investigators would like to determine whether they can find markers in the blood which predict worsening lung injury.

Condition or disease Intervention/treatment Phase
Lung Cancer Lung Metastases Drug: Nintedanib Drug: Prednisone Other: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 33 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Phase II Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of Nintedanib (BIBF 1120) + Prednisone Taper in Patients With Radiation Pneumonitis
Study Start Date : July 2015
Estimated Primary Completion Date : July 2023
Estimated Study Completion Date : July 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Pneumonia Steroids

Arm Intervention/treatment
Experimental: Nintedanib + Prednisone
The initial dose of nintedanib will be 150mg two times per day orally according to study protocol. Nintedanib will be taken for 12 weeks. Patients will be given a prednisone taper (40mg prednisone daily for 2 weeks, followed by a strict dose taper of 10mg every 2 weeks for 4 weeks, followed by 10mg for one week and 5mg for one week, for a total duration on prednisone of 8 weeks).
Drug: Nintedanib
Other Name: BIBF 1120

Drug: Prednisone
Experimental: Placebo + Prednisone
Placebo will be taken for 12 weeks. Patients will be given a prednisone taper (40mg prednisone daily for 2 weeks, followed by a strict dose taper of 10mg every 2 weeks for 4 weeks, followed by 10mg for one week and 5mg for one week, for a total duration on prednisone of 8 weeks).
Drug: Prednisone
Other: Placebo

Primary Outcome Measures :
  1. Number of patients who are free from pulmonary exacerbations [ Time Frame: 12 months ]

    An acute exacerbation will be defined as (all criteria must be met):

    1. Unexplained worsening or development of cough, dyspnea, hypoxia, or pneumonitis lasting more than 4 days
    2. New or worsening diffuse pulmonary infiltrates on chest CT (with or without contrast) or new high resolution CT parenchymal abnormalities without significant pneumothorax or pleural effusion

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically/cytologically proven primary thoracic or breast malignancy, lymphoma or lung metastases (which are not required to be biopsy-proven) treated with definitive intent at MSK
  • Prior treatment with thoracic radiotherapy completed >4 weeks and ≤ 9 months prior to enrollment
  • Radiographic evidence of radiation pneumonitis on a CT scan of the chest with or without contrast
  • Newly diagnosed clinical grade 2 or higher radiation pneumonitis according to CTCAE version 4.0 criteria
  • Age≥18 years
  • KPS > 70%
  • Reduction of any acute toxicity from radiation treatment to grade 1
  • Written informed consent signed prior to entry into the study

Exclusion Criteria:

  • Current oral steroid use > 4 weeks prior to registration
  • Ongoing treatment with radiotherapy to thorax, cytotoxic or biological therapies for this malignancy, except the following therapies which are permitted: Pembrolizumab, Nivolumab, Afatinib and all hormonal therapies.
  • Mean esophageal radiation dose >45 Gy
  • Diagnosis of diffuse radiation pneumonitis
  • Untreated or symptomatic brain metastases or leptomeningeal disease
  • Liver metastases
  • Other active malignancies requiring oncologic treatment (Note: non-melanoma skin cancer, superficial bladder cancer etc. are eligible)
  • Radiographic evidence of cavitary or necrotic tumor and local invasion of major blood vessels
  • Active chronic Hepatitis C and/or B infection
  • Gastrointestinal disorders that would interfere with drug absorption
  • AST > 1.5 x ULN, ALT>1.5 x ULN and Bilirubin > 1.5 x ULN
  • ≥ Grade 2 proteinuria, creatinine >1.5x ULN or GFR <45 ml/min
  • Other investigational therapy received within 8 weeks prior to screening visit
  • Pregnant women or women who are breast feeding or of child bearing potential not using a highly effective method of birth control for at least one month prior to enrollment1
  • Sexually active males not committing to birth control during the course of the study (except if their partner is not of childbearing potential)
  • Conditions that may affect the patient's ability to participate in this trial, e.g. known or suspected active alcohol or drug abuse
  • Inherited predisposition to bleeding or thrombosis, INR >2, PT and PTT >1.5x ULN
  • History of bleeding disorders or thrombotic events, e.g. hemorrhagic or thrombotic events within 12 months, clinically significant or tumor-related hemoptysis, active gastrointestinal bleeding or ulcers or major injuries or surgery
  • ANC < 1.5 K/mcL, Platelets < 100 K/mcL, Hemoglobin < 9.0 g/dl
  • Concomitant treatment with any of the following drugs: azathioprine, cyclophosphamide, cyclosporine, pirfenidone, full dose anticoagulation (vitamin K antagonists, dabigatran, heparin, etc.), fibrinolysis and high dose anti-platelet therapy (ex. Plavix 150mg)^2 Myocardial infarction or unstable angina within 6 or 1 month of starting nintedanib treatment, respectively
  • Known inherited predisposition to thrombosis
  • Patient with a history of a thrombotic event within 12 months of starting nintedanib treatment
  • Known predisposition to bleeding
  • Patients with severe hepatic impairment
  • History of a gastrointestinal perforation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02496585

Layout table for location information
United States, Massachusetts
Brigham and Women's Hospital (Data Collection Only)
Boston, Massachusetts, United States, 02115
United States, New Jersey
Memorial Sloan Kettering Cancer Center at Basking Ridge
Basking Ridge, New Jersey, United States, 07920
Memorial Sloan Kettering Monmouth
Middletown, New Jersey, United States, 07748
Memorial Sloan Kettering Bergen
Montvale, New Jersey, United States, 07645
United States, New York
Memorial Sloan Kettering Cancer Center @ Suffolk
Commack, New York, United States, 11725
Memorial Sloan Kettering Westchester
Harrison, New York, United States, 10604
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065
Memorial Sloan Kettering at Mercy Medical Center
Rockville Centre, New York, United States
Memorial Sloan Kettering Nassau
Uniondale, New York, United States, 11553
United States, Pennsylvania
Lehigh Valley Health Network (Data Collection Only)
Allentown, Pennsylvania, United States, 18103
United States, Texas
Houston, Texas, United States, 77030
United States, Utah
Myriad Genetic Laboratory (Data or Specimen Analysis Only)
Salt Lake City, Utah, United States, 84108
Sponsors and Collaborators
Memorial Sloan Kettering Cancer Center
Boehringer Ingelheim
Layout table for investigator information
Principal Investigator: Andreas Rimner, MD Memorial Sloan Kettering Cancer Center
Additional Information:
Layout table for additonal information
Responsible Party: Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov Identifier: NCT02496585    
Other Study ID Numbers: 14-167
First Posted: July 14, 2015    Key Record Dates
Last Update Posted: July 20, 2022
Last Verified: July 2022
Keywords provided by Memorial Sloan Kettering Cancer Center:
Nintedanib (BIBF 1120)
Radiation Pneumonitis
Additional relevant MeSH terms:
Layout table for MeSH terms
Radiation Pneumonitis
Respiratory Tract Infections
Lung Diseases
Respiratory Tract Diseases
Lung Diseases, Interstitial
Lung Injury
Radiation Injuries
Wounds and Injuries
Anti-Inflammatory Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action